rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    EYPT
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      EyePoint at UBS biopharma conference: DME hopes offset wet AMD setback
      Nov 17Investing.comAMDEYPTUBS
      EyePoint at Jefferies Global Healthcare Conference: pivots to dme
      Nov 16Investing.comEYPTJEF
      Stifel cuts EyePoint stock price target on trial setbacks
      Nov 13Investing.comEYPT
      EyePoint Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
      Nov 12Yahoo FinanceEYPT
      Earnings call transcript: EyePoint shares fall after q3 2026 loss and wet amd setback
      Nov 12Investing.comEYPT
      EyePoint Pharmaceuticals Q3 2026 Earnings Call Transcript
      Nov 12BenzingaEYPT
      EyePoint (EYPT) Reports Q3 Loss, Beats Revenue Estimates
      Nov 12Yahoo FinanceEYPT
      EyePoint: Q3 Earnings Snapshot
      Nov 12Yahoo FinanceEYPT
      EyePoint Reports Third Quarter 2026 Financial Results and Provides Recent Corporate Developments
      Nov 12Yahoo FinanceEYPT
      EyePoint at Stifel 2026 Healthcare Conference 2026: pivot to DME
      Nov 10Investing.comEYPTSF
      EyePoint at Guggenheim conference: DME becomes the main focus
      Nov 9Investing.comEYPT
      EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings
      Nov 6Yahoo FinanceEYPT
      EyePoint to Report Third Quarter 2026 Financial Results on November 12, 2026
      Nov 5Yahoo FinanceEYPT
      EyePoint Stock: DME Upside Remains, But Financing Could Consume Most Of It (NASDAQ:EYPT)

      EyePoint is downgraded from a speculative Strong Buy to a Hold following LUCIA’s failure, pending greater clarity on cash runway. Read more on EYPT stock here.

      Oct 29Seeking AlphaEYPT
      EyePoint, Inc. (EYPT) Discusses LUCIA Phase III Topline Results for DURAVYU in Wet Age-Related Macular Degeneration - Slideshow (NASDAQ:EYPT) 2026-10-21
      Oct 21Seeking AlphaEYPT
      EyePoint (EYPT) Stock Sees Fair Value Cut After Duravyu Trial Setbacks
      Oct 21Yahoo FinanceEYPT
      EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals
      Oct 20MorningstarEYPT
      EyePoint halves workforce and ends Phase III trial early after endpoint miss
      Oct 20Yahoo FinanceEYPT
      JPMorgan Downgrades EyePoint Pharmaceuticals to Underweight From Neutral
      Oct 20Yahoo FinanceEYPT
      RBC Capital cuts EyePoint stock price target on trial miss
      Oct 20Investing.comEYPT
      Mizuho downgrades EyePoint stock rating on trial failure
      Oct 20Investing.comEYPT
      RBC Capital Adjusts Price Target on EyePoint Pharmaceuticals to $1 From $5, Keeps Sector Perform, Speculative Risk
      Oct 20Yahoo FinanceEYPT
      Mizuho Downgrades EyePoint Pharmaceuticals to Neutral From Outperform, Adjusts PT to $0.50 From $39
      Oct 20Yahoo FinanceEYPT
      JPMorgan downgrades EyePoint stock rating on trial failures
      Oct 20Investing.comEYPT
      AMZN, CLF, IRON, SLN, EYPT: 5 Trending Stocks Today - Amazon.com (NASDAQ:AMZN)

      Major U.S. indices ended mixed on Monday, with the Dow Jones Industrial Average slipping 0.07% to 51,966.03.

      Oct 20BenzingaEYPTIRONSLNCLF
      EyePoint Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into EyePoint Pharmaceuticals (EYPT)
      Oct 19MorningstarEYPT
      EYPT Stock Layoffs: What to Know About the Latest EyePoint Job Cuts
      Oct 19BarchartEYPT
      EyePoint: Stock Takes Shellacking On Second Pivotal Eye Disease Study Miss (NASDAQ:EYPT)
      Oct 19Seeking AlphaEYPT
      EyePoint to halve workforce after experimental drug fails second late-stage trial
      Oct 19ReutersEYPT
      EyePoint Slashing Workforce, Halting Clinical Trials to Pivot Focus
      Oct 19BenzingaEYPT
      EyePoint Slashing Workforce, Halting Clinical Trials to Pivot Focus - EyePoint (NASDAQ:EYPT)

      EyePoint cuts 53% of staff and halts wet AMD trials after DURAVYU misses its Phase 3 primary endpoint, pivoting its focus entirely to DME.

      Oct 19BenzingaEYPT
      Jefferies downgrades Eyepoint stock rating on trial miss
      Oct 19Investing.comEYPT
      EyePoint crashes as pivotal wet AMD trial fails, prompting 53% workforce cut
      Oct 19Yahoo FinanceEYPT
      EyePoint Announces 53% Workforce Reduction Following Phase 3 DURAVYU Trial Results
      Oct 19Yahoo FinanceEYPT
      EyePoint stock down on late-stage trial setback (EYPT:NASDAQ)
      Oct 19Seeking AlphaEYPT
      Why is EyePoint stock collapsing today?
      Oct 19Investing.comEYPT
      EyePoint Stock Sinks 82% After Key Eye Drug Fails and Staff Is Slashed. Will a Strategy Shift Save It?

      EyePoint stock is heading for its largest single-day percentage drop on record.

      Oct 19Barron'sEYPT
      EyePoint Pharmaceuticals to Cut 53% of Workforce After Eye Disease Drug Trial Setback
      Oct 19Yahoo FinanceEYPT
      EyePoint to cut 53% of workforce after phase 3 trial miss
      Oct 19Investing.comEYPT
      EyePoint to cut workforce by half after experimental drug fails second late-stage trial
      Oct 19Yahoo FinanceEYPT
      EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU™ in Wet AMD
      Oct 19Yahoo FinanceEYPT
      EyePoint Announces Strategic Prioritization
      Oct 19Yahoo FinanceEYPT
      Here's Why You Should Add EYPT Stock to Your Portfolio Now
      Oct 15Yahoo FinanceEYPT
      JonesTrading Sticks to Its Buy Rating for EyePoint Pharmaceuticals (EYPT)

      Detailed price information for Eyepoint Inc (EYPT-Q) from The Globe and Mail including charting and trades.

      Sep 28The Globe and MailEYPT
      EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

      WATERTOWN, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employee as inducement award outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 3,00

      Sep 16Yahoo FinanceEYPT
      EyePoint at Morgan Stanley conference: duravyu path stays open
      Sep 15Investing.comEYPTMS
      Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), EyePoint Pharmaceuticals (EYPT) and Abbott Laboratories (ABT)

      Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

      Sep 11The Globe and MailBBIOEYPT
      EyePoint at Cantor conference: mixed trial data leaves key catalyst ahead
      Sep 10Investing.comEYPT
      EyePoint at Citi summit: wet AMD setback, but path stays open
      Sep 9Investing.comEYPT
      INVESTIGATION ALERT: Investigation Launched Into EyePoint, Inc. (EYPT), Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP
      Sep 8BarchartEYPT

      This is the newest page. Registered accounts read further back.